2nd Quarter - Report

CAPITOL HILL CONSULTING GROUP for NOVARTIS CORPORATION

Firm
Client
Income
$30,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

General Corporate Tax Reform; Orphan Drug Credit; Research and Experimentation Tax Credit Extension; International corporate taxation; Inversion regulations and legislation

LobbyistCovered position, as disclosed
DAVID JORY —
BRIAN SUTTER New Staff Dir., W&M Health Subcommittee, Chairman Dave Camp April, 2013 - Dec. 2014; Professional Staff, W&M Health Subcommittee, Chairman Dave Camp, Jan. 2011 - April 2013;Leg Dir., Rep. Dave Camp, May '08 - Jan.,'11 Leg Asst.Rep Camp, Feb '03-May'08;

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Health Issues HCR

Issues related to Biosimilar Approvals and implementation of biologic price competition and innovation act. H.R. 5182, the Promoting Life-Saving New Therapies for Neonates Act of 2016

LobbyistCovered position, as disclosed
DAVID JORY —
BRIAN SUTTER Staff Dir., W&M Health Subcommittee, Chairman Dave Camp April, 2013 - Dec. 2014; Professional Staff, W&M Health Subcommittee, Chairman Dave Camp, Jan. 2011 - April 2013;Leg Dir., Rep. Dave Camp, May '08 - Jan.,'11 Leg Asst.Rep Camp, Feb '03-May'08;

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 5182 (114th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.